Japan's Mitsubishi Tanabe expected to have fast-production flu vaccine ready by 2019

Japan's Mitsubishi Tanabe is moving forward with a flu vaccine that is produced by implanting genetic material from the flu virus into tobacco leaves, which then produce flulike particles containing antigens to provoke an immune response. The key benefit of the tobacco manufacturing process is that it requires only one month to produce a vaccine, compared to the 6 months required to produce a traditional egg-based jab. The company hopes to get the vaccine to market by 2018 or 2019. More from FierceVaccines

Suggested Articles

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.